Please provide your email address to receive an email when new articles are posted on . Adjuvant ado-trastuzumab emtansine improved survival compared with trastuzumab for early HER2-positive ...

Recent research has focused on enhancing the effectiveness of these vaccines through the use of adjuvants—substances that boost the body's immune response to the vaccine. This summary highlights ...

Cohere on Thursday debuted its early access program for its AI agent platform called North, deepening its focus on the enterprise. Co-founder Nick Frosst indicated that he's happy to cede the ...

At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who ...

Cohere Capital Partners (“Cohere”), a Boston-based private equity firm focused on investing in leading tech-enabled lower middle market companies, announced today that it has closed Cohere ...

Cohere, an AI startup focused on enterprise technology, unveiled North on Thursday — an all-in-one platform combining large language models, multimodal search, and agents to help its customers ...

New customers, revenue growth, deals, and industry accolades strengthen Cohere's position as the transformation leader in intelligent prior authorization solutions Last year, Cohere secured nine ...